One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Virtual reality: the dawn of a new ERA
Kate I Stevens, Giuseppe Palladino, Juan C Almiron, Monica Fontana, Christoph Wanner
doi : 10.1093/ndt/gfaa255
Volume 36, Issue 1, January 2021, Pages 1–4
Every obstruction does not need a stent: an important lesson from the ISCHEMIA-CKD trial for kidney-transplant surgeons
Panagiotis I Georgianos, Rajiv Agarwal
doi : 10.1093/ndt/gfaa157
Volume 36, Issue 1, January 2021, Pages 4–8
COVID-19 and policy changes for kidney disease: the need for a ‘decade of the kidney’
Raymond Vanholder, Norbert Lameire
doi : 10.1093/ndt/gfaa339
Volume 36, Issue 1, January 2021, Pages 8–11
Rituximab in fibrillary glomerulonephritis: fumble or forward progress?
Shikha Wadhwani, Kenar D Jhaveri
doi : 10.1093/ndt/gfaa186
Volume 36, Issue 1, January 2021, Pages 11–13
Personalizing potassium management in patients on haemodialysis
Rosa D Wouda, Liffert Vogt, Ewout J Hoorn
doi : 10.1093/ndt/gfaa213
Volume 36, Issue 1, January 2021, Pages 13–18
Imaging the kidney: from light to super-resolution microscopy
Maria Lucia Angelotti, Giulia Antonelli, Carolina Conte, Paola Romagnani
doi : 10.1093/ndt/gfz136
Volume 36, Issue 1, January 2021, Pages 19–28
The important achievements in kidney physiological and pathophysiological mechanisms can largely be ascribed to progress in the technology of microscopy. Much of what we know about the architecture of the kidney is based on the fundamental descriptions of anatomic microscopists using light microscopy and later by ultrastructural analysis provided by electron microscopy. These two techniques were used for the first classification systems of kidney diseases and for their constant updates. More recently, a series of novel imaging techniques added the analysis in further dimensions of time and space.
One concept does not fit all: the immune system in different forms of acute kidney injury
Hans-Joachim Anders, Louise Wilkens, Barbara Schraml, Julian Marschner
doi : 10.1093/ndt/gfaa056
Volume 36, Issue 1, January 2021, Pages 29–38
Renal and immune systems maintain body homoeostasis during physiological fluctuations and following tissue injury. The immune system plays a central role during acute kidney injury (AKI), adapting evolutional systems programmed for host defence and minimizing unnecessary collateral damage. Indeed, depending upon the disease context, the impact of the immune system upon the manifestations and consequences of AKI can be quite different.
Cystatin C to predict renal disease and cardiovascular risk
Jennifer S Lees, Patrick B Mark
doi : 10.1093/ndt/gfaa152
Volume 36, Issue 1, January 2021, Pages 39–41
European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D
Pieter Evenepoel, John Cunningham, Serge Ferrari, Mathias Haarhaus, Muhammad Kassim Javaid ...
doi : 10.1093/ndt/gfaa192
Volume 36, Issue 1, January 2021, Pages 42–59
Controlling the excessive fracture burden in patients with chronic kidney disease (CKD) Stages G4–G5D remains an impressive challenge. The reasons are 2-fold. First, the pathophysiology of bone fragility in patients with CKD G4–G5D is complex and multifaceted, comprising a mixture of age-related (primary male/postmenopausal), drug-induced and CKD-related bone abnormalities. Second, our current armamentarium of osteoporosis medications has not been developed for, or adequately studied in patients with CKD G4–G5D, partly related to difficulties in diagnosing osteoporosis in this specific setting and fear of complications.
Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease
Anna Faivre, Elena Katsyuba, Thomas Verissimo, Maja Lindenmeyer, Renuga Devi Rajaram ...
doi : 10.1093/ndt/gfaa124
Volume 36, Issue 1, January 2021, Pages 60–68
Nicotinamide adenine dinucleotide (NAD+) is a ubiquitous coenzyme involved in electron transport and a co-substrate for sirtuin function. NAD+ deficiency has been demonstrated in the context of acute kidney injury (AKI).
Evidence of an intestinal phosphate transporter alternative to type IIb sodium-dependent phosphate transporter in rats with chronic kidney disease
Yasuhiro Ichida, Shuichi Ohtomo, Tessai Yamamoto, Naoaki Murao, Yoshinori Tsuboi ...
doi : 10.1093/ndt/gfaa156
Volume 36, Issue 1, January 2021, Pages 68–75
Phosphate is absorbed in the small intestine via passive flow and active transport.NaPi-IIb, a type II sodium-dependent phosphate transporter, is considered to mediate active phosphate transport in rodents. To study the regulation of intestinal phosphate transport in chronic kidney disease (CKD), we analyzed the expression levels of NaPi-IIb, pituitary-specific transcription factor 1 (PiT-1) and PiT-2 and the kinetics of intestinal phosphate transport using two CKD models.
Aberrant mucosal immunoreaction to tonsillar microbiota in immunoglobulin A nephropathy
Hiroki Yamaguchi, Shin Goto, Nao Takahashi, Masafumi Tsuchida, Hirofumi Watanabe ...
doi : 10.1093/ndt/gfaa223
Volume 36, Issue 1, January 2021, Pages 75–86
Immunoglobulin A nephropathy (IgAN) is the most common glomerulonephritis worldwide, characterized by mesangial polymeric IgA1 deposition. IgAN is believed to develop owing to aberrant mucosal immunoreaction against commensals in the tonsils. However, the exact interrelation between pathogenic IgA and mucosal microbiota in IgAN patients is unclear.
Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA
ERA-EDTA Council , ERACODA Working Group
doi : 10.1093/ndt/gfaa314
Volume 36, Issue 1, January 2021, Pages 87–94
Diabetes, hypertension and cardiovascular disease have been listed as risk factors for severe coronavirus disease 2019 (COVID-19) since the first report of the disease in January 2020. However, this report did not mention chronic kidney disease (CKD) nor did it provide information on the relevance of estimated glomerular filtration rate (eGFR) or albuminuria. As the disease spread across the globe, information on larger populations with greater granularity on risk factors emerged. The recently published OpenSAFELY project analysed factors associated with COVID-19 death in 17 million patients.
Muscle mass and plasma myostatin after exercise training: a substudy of Renal Exercise (RENEXC)—a randomized controlled trial
Yunan Zhou, Matthias Hellberg, Thomas Hellmark, Peter H?glund, Naomi Clyne
doi : 10.1093/ndt/gfz210
Volume 36, Issue 1, January 2021, Pages 95–103
Sarcopenia increases as renal function declines and is associated with higher morbidity and mortality. Myostatin is a negative regulator of muscle growth. Its expression in response to exercise is unclear. In this prespecified substudy of the Renal Exercise (RENEXC) trial, we investigated the effects of 12?months of exercise training on sarcopenia, muscle mass and plasma myostatin and the relationships between physical performance, muscle mass and plasma myostatin.
Treatment of fibrillary glomerulonephritis with rituximab: a 12-month pilot study
Stephen B Erickson, Ladan Zand, Samih H Nasr, Mariam P Alexander, Nelson Leung ...
doi : 10.1093/ndt/gfaa065
Volume 36, Issue 1, January 2021, Pages 104–110
Fibrillary glomerulonephritis (FGN) is a rare type of glomerulonephritis with poor prognosis, with no known effective therapies available for treatment. The objective of the study was to evaluate the efficacy and safety of rituximab in treatment of patients with FGN and to investigate the effect of rituximab on DNAJB9 levels.
Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial
Sunil Bhandari, Philip A Kalra, Mario Berkowitz, Diogo Belo, Lars L Thomsen ...
doi : 10.1093/ndt/gfaa011
Volume 36, Issue 1, January 2021, Pages 111–120
The optimal intravenous (IV) iron would allow safe correction of iron deficiency at a single infusion over a short time. The FERWON-NEPHRO trial evaluated the safety and efficacy of iron isomaltoside 1000/ferric derisomaltose (IIM) in patients with non-dialysis-dependent chronic kidney disease and iron deficiency anaemia.
Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study
Maarten A De Jong, Michele F Eisenga, Adriana J van Ballegooijen, Joline W J Beulens, Marc G Vervloet ...
doi : 10.1093/ndt/gfz266
Volume 36, Issue 1, January 2021, Pages 121–128
Fibroblast growth factor 23 (FGF23), a phosphate-regulating hormone that increases early in the course of chronic kidney disease (CKD), is associated with disease progression in patients with established CKD. Here we aimed to investigate the association between plasma FGF23 and new-onset CKD in the general population.
Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease
Ahmed A Awan, Carl P Walther, Peter A Richardson, Maulin Shah, Wolfgang C Winkelmayer ...
doi : 10.1093/ndt/gfz192
Volume 36, Issue 1, January 2021, Pages 129–136
Anemia is associated with adverse outcomes in those with chronic kidney disease (CKD). We examined the association of absolute and functional iron deficiency anemia (IDA) with adverse outcomes (cardiovascular hospitalization, dialysis and mortality) in those with nondialysis-dependent CKD.
Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study
Simon D Roger, Philip T Lavin, Edgar V Lerma, Peter A McCullough, Javed Butler ...
doi : 10.1093/ndt/gfz285
Volume 36, Issue 1, January 2021, Pages 137–150
Sodium zirconium cyclosilicate (SZC; formerly ZS-9) is a selective potassium (K+) binder for the treatment of adults with hyperkalaemia. This post hoc analysis of an open-label, single-arm trial (NCT02163499) compared SZC efficacy and safety >12?months among outpatients with hyperkalaemia and Stages 4 and 5 chronic kidney disease (CKD) versus those with Stages 1–3 CKD.
Prescription patterns of dialysate potassium and potassium binders and survival on haemodialysis—the French Renal Epidemiology and Information Network registry
Lucile Mercadal, Oriane Lambert, Cécile Couchoud, Marie Metzger, Stéphane Edet ...
doi : 10.1093/ndt/gfaa077
Volume 36, Issue 1, January 2021, Pages 151–159
Management of potassium disorders in patients on haemodialysis (HD) is complex. We studied prescription patterns of dialysate potassium and potassium binders, and their associations with patient survival.
The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation
Nahid Tabibzadeh, Angelo Karaboyas, Bruce M Robinson, Philipp A Csomor, David M Spiegel ...
doi : 10.1093/ndt/gfaa195
Volume 36, Issue 1, January 2021, Pages 160–169
Optimal parathyroid hormone (PTH) control during non-dialysis chronic kidney disease (ND-CKD) might decrease the subsequent risk of parathyroid hyperplasia and uncontrolled secondary hyperparathyroidism (SHPT) on dialysis. However, the evidence for recommending PTH targets and therapeutic strategies is weak for ND-CKD. We evaluated the patient characteristics, treatment patterns and PTH control over the first year of haemodialysis (HD) by PTH prior to HD initiation.
Bleeding risk of haemodialysis and peritoneal dialysis patients
Anita van Eck van der Sluijs, Alferso C Abrahams, Maarten B Rookmaaker, Marianne C Verhaar, Willem Jan W Bos ...
doi : 10.1093/ndt/gfaa216
Volume 36, Issue 1, January 2021, Pages 170–175
Dialysis patients have an increased bleeding risk as compared with the general population. However, there is limited information whether bleeding risks are different for patients treated with haemodialysis (HD) or peritoneal dialysis (PD). From a clinical point of view, this information could influence therapy choice. Therefore the aim of this study was to investigate the association between dialysis modality and bleeding risk.
Higher mortality risk among kidney transplant recipients than among estimated glomerular filtration rate–matched patients with CKD—preliminary results
Lynda Cheddani, Sophie Liabeuf, Marie Essig, Renaud Snanoudj, Christian Jacquelinet ...
doi : 10.1093/ndt/gfaa026
Volume 36, Issue 1, January 2021, Pages 176–184
Although kidney transplantation prolongs survival relative to dialysis, it is associated with a higher death rate than in the general population. The objective of the present study was to assess and compare the risk of mortality and frequency of non-lethal cardiovascular (CV) events in kidney transplant recipients (KTRs) beyond 1?year after successful transplantation versus patients with chronic kidney disease (CKD) using propensity score–matched analysis of estimated glomerular filtration rate (eGFR) and other parameters.
Acute kidney injury in renal transplant recipients undergoing cardiac surgery
Gregory L Hundemer, Anand Srivastava, Kirolos A Jacob, Neeraja Krishnasamudram, Salman Ahmed ...
doi : 10.1093/ndt/gfaa063
Volume 36, Issue 1, January 2021, Pages 185–196
Acute kidney injury (AKI) is a key risk factor for chronic kidney disease in the general population, but has not been investigated in detail among renal transplant recipients (RTRs). We investigated the incidence, severity and risk factors for AKI following cardiac surgery among RTRs compared with non-RTRs with otherwise similar clinical characteristics.
